Alert: Legal Psychedelics Could Be the Next Cannabis Stocks!

Psychedelics have been legalized or decriminalized in two states this week. Canadian stocks like Mind Medicine (MindMed) Inc. (OTC:MMED) could be at the forefront.

| More on:
edit Jars of marijuana

Image source: Getty Images

While the world waits with bated breath for the results of the U.S. presidential election, voters in key U.S. states have already made a historic decision. Two key states have decriminalized the use of psychedelics for medical purposes. This could be an (extremely) early sign that psychedelics could become legalized on par with marijuana soon.

Here’s why investors should follow these latest developments closely.

Background on psychedelic drugs

Johns Hopkins University—the U.S.’s oldest research university—launched a dedicated center for psychedelic studies. While it’s still early, researchers believe the substance could help treat certain psychological conditions such as depression and post-traumatic stress disorder (PTSD). 

An estimated 17.3 million people suffer from depression in the United States alone, which goes to show how critical this research is. 

The U.S. election

Yesterday’s election for the Presidential race is still too close to call. However, Americans were voting for a lot more than just the White House. Senate seats, for example, were up for grabs as were key state legislation measures. 

Yesterday, Oregon voters passed Measure 109 – a move that could allow medical professionals and researchers to study the benefits of psychedelic drugs such as psilocybin. Popular known as magic mushrooms, these drugs are prohibited in nearly every part of the world. However, interest in their medical benefits has been growing in recent years. 

Similarly, voters in Washington D.C passed Initiative 81 yesterday to decriminalize the use of psychedelic drugs. Yet another indication that public perception about magic mushrooms is shifting. If their medical benefits are proven, more states and perhaps other countries could follow this lead. 

Some industry experts believe the market could be as big as US$6.8 billion (C$8.9 billion) by 2027 if the wave of legalization and medical use continues. That’s a big market, but not nearly as big as the global cannabis industry. Nevertheless, since investors have overlooked this space and there’s only a handful of players, the opportunities seem attractive. 

Canadian psychedelic stocks

A few medical startups have listed on Canadian stock exchanges in recent years. The most noteworthy, perhaps, is Mind Medicine (MindMed) Inc. (OTC:MMED), which is listed on the NEO exchange and is available over the counter. 

Cannabis titan Bruce Linton, the founder and former CEO of Canopy Growth, is a MindMed director. The company is also backed by Shark Tank’s Kevin O’Leary, who told Fast Company, “this could save lives, cure depression, help alcoholism, get people off opioids—why wouldn’t I want to be invested?”  

MindMed stock is up 5.5% today on news of Oregon and D.C.’s ballot initiatives. The company is worth $334 million, but could surge a lot higher if the trend continues and more investors get involved in this space. 

Bottom line

Decisive votes in two American states have paved the way for the legalization of psychedelic drugs. This breakthrough could add tremendous value to Canadian startups like MindMed that are working on developing these substances. 

While the market won’t be as big as legal cannabis, it will certainly create extensive shareholder value for early investors. Keep an eye on this stock as the industry matures over the next few years. 

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Vishesh Raisinghani has no position in any of the stocks mentioned.

More on Investing

Top view of people having party, gathering, celebrating together
Investing

Plant-Based Foods Growth: Why I’m Buying This TSX Stock on the Dip

SunOpta (TSX:SOY) is a Minneapolis-based company that manufactures and sells plant-based and fruit-based food and beverage products to a variety …

Read more »

Coronavirus written newspaper close up shot to the text.
Tech Stocks

The 2 Best Tech Stocks to Buy Today for Low-Risk Investors

Overvalued tech stocks are undergoing a major correction after inflating on the back of high liquidity from fiscal stimulus packages. …

Read more »

crypto blockchain
Cryptocurrency

How Cheap Can Crypto Mining Stocks Get Before They Are Worth a Buy?

Over the last two years, during the significant rallies in the crypto industry, some of the biggest gainers and best …

Read more »

Aircraft wing plane
Coronavirus

Air Canada (TSX:AC): Is $22/Share Cheap or Expensive?

The TSX Composite Index corrected 2.3% since December 30, 2021, as tech stocks saw a huge selloff over the anticipation …

Read more »

exchange traded funds
Energy Stocks

3 Sector-Specific ETFs to Consider

Exposure to a specific sector doesn’t make sense from a diversification perspective, but it is often a good way to …

Read more »

silver metal
Metals and Mining Stocks

1 Reeling Silver Stock to Consider Today

Aya Gold & Silver (TSX:AYA) is a Montreal-based company that is engaged in the acquisition, exploration, evaluation, and development of …

Read more »

Dividend Stocks

3 Dividend Stocks I’d Buy and Never Sell

Canadian National Railway (TSX:CNR)(NYSE:CNI) has many things going for it — the least of which is its history as an …

Read more »

Choose a path
Tech Stocks

Is Ripple Primed for 100% Growth in 2022?

From an investment perspective, most cryptocurrencies seem similar. Almost all of them seem volatile, and while some get more limelight …

Read more »